Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
Developing a Blood-Based Biomarker for the Early Diagnosis of PD
April 1, 2025
Developing a blood-based biomarker targeting α-synuclein fragments for the early diagnosis of PD
Introduction
Parkinson’s disease (PD) affects millions worldwide and currently has no cure. Treatments focus only on managing symptoms, explaining why there is a pressing need for biomarkers and advanced diagnostic tools to enable earlier detection and better disease management. In the early stages of PD, α-synuclein—can be cleaved by Calpain I, presenting a potential target for biomarker development.
The aim of this study was to develop a sensitive immunoassay that detects α-synuclein fragments.
Poster
Conclusion
α-Synuclein fragments cleaved by calpain I are key early drivers of Parkinson’s disease pathology. This blood-based biomarker holds promise for enabling early diagnosis and identifying patients who are likely to respond to treatment.
